The FDA and the CDC could care less about your health. These two agencies are in the pocket of Pig Pharma and the rest of the medical industrial complex:
FDA Helps Drug Company Increase Price of Live Saving Medicine 7,000 Percent
Matt Agorist February 11, 2017
In what is sure to be misinterpreted as the horrors of the evil free market, a prescription drug has increased in price in the US more than 7,000 fold. The problem here is that the price increase was solely a function of a government-granted monopoly on the drug, which has been on the international market for years.
In a Thursday press release, the Food and Drug Administration (FDA) granted approval for a drug by Marathon Pharmaceuticals, a US company focused solely on the development of new treatments for rare diseases. They may now begin selling the corticosteroid drug Deflazacort, under the brand name Emflaza.
Thanks to the FDA, Marathon now has a monopoly on the drug and, without competition, they are now able to sell this beneficial treatment for Duchenne muscular dystrophy for $89,000 a year — a sharp increase from the international market price of $1,200 a year.
Duchenne muscular dystrophy (DMD) is a rare genetic disease that causes heart and respiratory conditions, usually in younger men. As DMD progresses, patients lose muscle strength and usually end up confined to a wheelchair by the time they reach their early teens.
According to the FDA, patients with DMD typically do not live past their 20s or 30s.
“This is the first treatment approved for a wide range of patients with Duchenne muscular dystrophy,” Billy Dunn, director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research, said in the press release. “We hope that this treatment option will benefit many patients with DMD.”
However, thanks to the FDA, it will only be beneficial to those who can afford the insane price tag of $89,000…
Read More Here: